Advertisement

Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount

  • Vladimir Tolmachev
  • Daniel Rosik
  • Helena Wållberg
  • Anna Sjöberg
  • Mattias Sandström
  • Monika Hansson
  • Anders Wennborg
  • Anna Orlova
Original Article

Abstract

Introduction

Overexpression of epidermal growth factor receptor (EGFR) is a prognostic and predictive biomarker in a number of malignant tumours. Radionuclide molecular imaging of EGFR expression in cancer could influence patient management. However, EGFR expression in normal tissues might complicate in vivo imaging. The aim of this study was to evaluate if optimization of the injected protein dose might improve imaging of EGFR expression in tumours using a novel EGFR-targeting protein, the DOTA-ZEGFR:2377 Affibody molecule.

Methods

An anti-EGFR Affibody molecule, ZEGFR:2377, was labelled with 111In via the DOTA chelator site-specifically conjugated to a C-terminal cysteine. The affinity of DOTA-ZEGFR:2377 for murine and human EGFR was measured by surface plasmon resonance. The cellular processing of 111In-DOTA-ZEGFR:2377 was evaluated in vitro. The biodistribution of radiolabelled Affibody molecules injected in a broad range of injected Affibody protein doses was evaluated in mice bearing EGFR-expressing A431 xenografts.

Results

Site-specific coupling of DOTA provided a uniform conjugate possessing equal affinity for human and murine EGFR. The internalization of 111In-DOTA-ZEGFR:2377 by A431 cells was slow. In vivo, the conjugate accumulated specifically in xenografts and in EGFR-expressing tissues. The curve representing the dependence of tumour uptake on the injected Affibody protein dose was bell-shaped. The highest specific radioactivity (lowest injected protein dose) provided a suboptimal tumour-to-blood ratio. The results of the biodistribution study were confirmed by γ-camera imaging.

Conclusion

The 111In-DOTA-ZEGFR:2377 Affibody molecule is a promising tracer for radionuclide molecular imaging of EGFR expression in malignant tumours. Careful optimization of protein dose is required for high-contrast imaging of EGFR expression in vivo.

Keywords

Affibody molecules EGFR Indium-111 Gamma-camera imaging 

Notes

Acknowledgments

This study was supported by grants from the Swedish Cancer Society (Cancerfonden) and the Swedish Research Council (Vetenskapsrådet). We thank Veronika Eriksson and the staff of the animal facility at Rudbeck Laboratory for technical assistance.

Disclosures

The authors, Orlova Anna, Helena Wållberg and Vladimir Tolmachev had earlier, and Daniel Rosik, Anna Sjöberg, Monika Hansson, Anders Wennborg have currently an affiliation (employment) with Affibody AB, Bromma, Sweden, which holds the intellectual property rights and trademarks for Affibody molecules.

References

  1. 1.
    Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(Suppl 4):S3–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Selvaggi G, Novello S, Torri V, Leonardo E, De Giuli P, Borasio P, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol. 2004;15:28–32.CrossRefPubMedGoogle Scholar
  3. 3.
    Zlobec I, Vuong T, Hayashi S, Haegert D, Tornillo L, Terracciano L, et al. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer. 2007;96:793–800.CrossRefPubMedGoogle Scholar
  4. 4.
    Nieto Y, Nawaz F, Jones RB, Shpall EJ, Nawaz S. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol. 2007;25:4405–13.CrossRefPubMedGoogle Scholar
  5. 5.
    Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, et al. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res. 2007;13:6579–84.CrossRefPubMedGoogle Scholar
  6. 6.
    Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res. 2005;11:8637–43.CrossRefPubMedGoogle Scholar
  7. 7.
    Kersting C, Packeisen J, Leidinger B, Brandt B, von Wasielewski R, Winkelmann W, et al. Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J Clin Pathol. 2006;59:585–90.CrossRefPubMedGoogle Scholar
  8. 8.
    Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350–6.PubMedGoogle Scholar
  9. 9.
    Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol. 2005;23:5560–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Giralt J, de las Heras M, Cerezo L, Eraso A, Hermosilla E, Velez D, et al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol. 2005;74:101–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Giltnane JM, Rydén L, Cregger M, Bendahl PO, Jirström K, Rimm DL. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol. 2007;25:3007–14.CrossRefPubMedGoogle Scholar
  12. 12.
    Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol. 2004;22:4772–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Choong LY, Lim S, Loh MC, Man X, Chen Y, Toy W, et al. Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics. Mol Cancer Ther. 2007;6:2828–42.CrossRefPubMedGoogle Scholar
  14. 14.
    Pantaleo MA, Nannini M, Maleddu A, Fanti S, Nanni C, Boschi S, et al. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Ann Oncol. 2009;20:213–26.CrossRefPubMedGoogle Scholar
  15. 15.
    Gelovani JG. Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography. Cancer Metastasis Rev. 2008;27:645–53.CrossRefPubMedGoogle Scholar
  16. 16.
    Mishani E, Abourbeh G, Eiblmaier M, Anderson CJ. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des. 2008;14:2983–98.CrossRefPubMedGoogle Scholar
  17. 17.
    Goldenberg A, Masui H, Divgi C, Kamrath H, Pentlow K, Mendelsohn J. Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody. J Natl Cancer Inst. 1989;81:1616–25.CrossRefPubMedGoogle Scholar
  18. 18.
    Divgi CR, Welt S, Kris M, Real FX, Yeh SD, Gralla R, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst. 1991;83:97–104.CrossRefPubMedGoogle Scholar
  19. 19.
    Reilly RM, Kiarash R, Sandhu J, Lee YW, Cameron RG, Hendler A, et al. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med. 2000;41:903–11.PubMedGoogle Scholar
  20. 20.
    Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging. 2007;34:850–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, et al. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm. 2008;23:619–31.CrossRefPubMedGoogle Scholar
  22. 22.
    Ping Li W, Meyer LA, Capretto DA, Sherman CD, Anderson CJ. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm. 2008;23:158–71.CrossRefPubMedGoogle Scholar
  23. 23.
    Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, Wouters BG, et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med. 2009;50:123–31.CrossRefPubMedGoogle Scholar
  24. 24.
    Cuartero-Plaza A, Martínez-Miralles E, Rosell R, Vadell-Nadal C, Farré M, Real FX. Radiolocalization of squamous lung carcinoma with 131I-labeled epidermal growth factor. Clin Cancer Res. 1996;2:13–20.PubMedGoogle Scholar
  25. 25.
    Rusckowski M, Qu T, Chang F, Hnatowich DJ. Technetium-99m labeled epidermal growth factor-tumor imaging in mice. J Pept Res. 1997;50:393–401.PubMedGoogle Scholar
  26. 26.
    Capala J, Barth RF, Bailey MQ, Fenstermaker RA, Marek MJ, Rhodes BA. Radiolabeling of epidermal growth factor with 99mTc and in vivo localization following intracerebral injection into normal and glioma-bearing rats. Bioconjug Chem. 1997;8:289–95.CrossRefPubMedGoogle Scholar
  27. 27.
    Sundberg AL, Orlova A, Bruskin A, Gedda L, Carlsson J, Blomquist E, et al. [(111)In]Bz-DTPA-hEGF: preparation and in vitro characterization of a potential anti-glioblastoma targeting agent. Cancer Biother Radiopharm. 2003;18(4):643–54.CrossRefPubMedGoogle Scholar
  28. 28.
    Babaei MH, Almqvist Y, Orlova A, Shafii M, Kairemo K, Tolmachev V. [99mTc]HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation. Oncol Rep. 2005;13:1169–75.PubMedGoogle Scholar
  29. 29.
    Velikyan I, Sundberg AL, Lindhe O, Höglund AU, Eriksson O, Werner E, et al. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med. 2005;46(11):1881–8.PubMedGoogle Scholar
  30. 30.
    Nygren PA. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J. 2008;275:2668–76.CrossRefPubMedGoogle Scholar
  31. 31.
    Nilsson FY, Tolmachev V. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel. 2007;10:167–75.PubMedGoogle Scholar
  32. 32.
    Orlova A, Feldwisch J, Abrahmsén L, Tolmachev V. Update: affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm. 2007;22:573–84.CrossRefPubMedGoogle Scholar
  33. 33.
    Nordberg E, Orlova A, Friedman M, Tolmachev V, Ståhl S, Nilsson FY, et al. In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. Oncol Rep. 2008;19:853–7.PubMedGoogle Scholar
  34. 34.
    Friedman M, Orlova A, Johansson E, Eriksson TL, Höidén-Guthenberg I, Tolmachev V, et al. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol. 2008;376:1388–402.CrossRefPubMedGoogle Scholar
  35. 35.
    Tolmachev V, Friedman M, Sandström M, Eriksson TL, Rosik D, Hodik M, et al. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med. 2009;50:274–83.CrossRefPubMedGoogle Scholar
  36. 36.
    Mume E, Orlova A, Larsson B, Nilsson AS, Nilsson FY, Sjöberg S, et al. Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjug Chem. 2005;16:1547–55.CrossRefPubMedGoogle Scholar
  37. 37.
    Ahlgren S, Orlova A, Rosik D, Sandström M, Sjöberg A, Baastrup B, et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjug Chem. 2008;19:235–43.CrossRefPubMedGoogle Scholar
  38. 38.
    Tolmachev V, Xu H, Wållberg H, Ahlgren S, Hjertman M, Sjöberg A, et al. Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules. Bioconjug Chem. 2008;19:1579–87.CrossRefPubMedGoogle Scholar
  39. 39.
    Tolmachev V, Orlova A, Wei Q, Bruskin A, Carlsson J, Gedda L. Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice. Cancer Biother Radiopharm. 2004;19:491–501.PubMedGoogle Scholar
  40. 40.
    Wållberg H, Orlova A. Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm. 2008;23:435–42.CrossRefPubMedGoogle Scholar
  41. 41.
    Maecke HR, Hofmann M, Haberkorn U. 68Ga-labeled peptides in tumor imaging. J Nucl Med. 2005;46(Suppl 1):172S–8S.PubMedGoogle Scholar
  42. 42.
    Biddlecombe GB, Rogers BE, de Visser M, Parry JJ, de Jong M, Erion JL, et al. Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14). Bioconjug Chem. 2007;18:724–30.CrossRefPubMedGoogle Scholar
  43. 43.
    Wållberg H, Ahlgren S, Widström C, Orlova A. Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-ZHER2:2395-Cys Affibody molecule for targeting of HER2-expressing tumors. Mol Imaging Biol 2009. doi: 10.1007/s11307-009-0238-8.
  44. 44.
    ImClone Systems Incorporated. Cetuximab: epidermal growth factor receptor (EGFR) antibody, version 9.0. ImClone Investigator Brochure. New York: ImClone Systems, 2003.Google Scholar
  45. 45.
    Gainkam LO, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008;49:788–95.CrossRefPubMedGoogle Scholar
  46. 46.
    de Jong M, Breeman WA, Bernard BF, et al. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0,TYR3]octreotide is dependent on the peptide amount. Eur J Nucl Med. 1999;26:693–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Schuhmacher J, Zhang H, Doll J, Mäcke HR, Matys R, Hauser H, et al. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog. J Nucl Med. 2005;46:691–9.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Vladimir Tolmachev
    • 1
    • 5
  • Daniel Rosik
    • 2
  • Helena Wållberg
    • 3
  • Anna Sjöberg
    • 2
  • Mattias Sandström
    • 4
  • Monika Hansson
    • 2
  • Anders Wennborg
    • 2
  • Anna Orlova
    • 1
  1. 1.Unit of Biomedical Radiation Sciences, Rudbeck LaboratoryUppsala UniversityUppsalaSweden
  2. 2.Affibody ABBrommaSweden
  3. 3.School of BiotechnologyRoyal Institute of TechnologyStockholmSweden
  4. 4.Department of Medical PhysicsUppsala University HospitalUppsalaSweden
  5. 5.Department of Medical Sciences, Nuclear MedicineUppsala UniversityUppsalaSweden

Personalised recommendations